InSightec announced that it is partnering with the American College of Radiology Imaging Network (ACRIN) to enroll patients in a phase II study assessing how effectively its ExAblate 2000 technology can ablate breast tumors.
The Haifa, Israel-based firm said that the ExAblate 2000 combines MRI with highly focused ultrasound to noninvasively thermally ablate tumors in the body. Currently, the technology is used to treat uterine fibroids.
The phase II trial is intended to demonstrate that ExAblate 2000 can effectively and noninvasively ablate localized tumors compared to conventional lumpectomy, according to the firm. The study will involve 200 patients at up to 10 sites worldwide, InSightec said.
By AuntMinnie.com staff writersNovember 22, 2005
Related Reading
InSightec gets Texas install, October 11, 2005
InSightec begins clinical trial enrollment, September 15, 2005
GE, Insightec ink new deal, August 17, 2005
GE partners with Insightec, October 25, 2004
InSightec gets $21 million infusion, September 29, 2004
Copyright © 2005 AuntMinnie.com
